Belite Bio (BLTE) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.77
- Surprise
- —
- Score today
- 5.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Belite Bio Reports Unaudited Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-12
- Belite Bio Q3 EPS $(0.65) Beats $(0.80) Estimate — benzinga, 2026-11-12
- Cisco Systems, Applied Materials On Deck Thursday As AI Demand Faces Test — benzinga, 2026-11-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates BLTE Sell at 5.7/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate.
What argues against it
- Quality below floor (1.6 < 4.0)
- Insider activity: 0.51%=heavy
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $155.94
- Price target
- $197.88
- Stop
- $145.02
- Upside to target
- +26.9%
- Reward-to-risk
- 2.8:1
Risk check: trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-12 — shown for context, not personalized investment advice.
BLTE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $6.28B
- P/E (fwd)
- 69.0
- 52-week range
- $105.88–$200.00
- Off 52-week high
- 22.0%
- RSI (14)
- 56
- Volume vs avg
- 1.64×
- Score today
- 5.7/10